HC Wainwright Comments on Stoke Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Stoke Therapeutics in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($2.51) per share for the year, up from their prior estimate of ($2.62). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.57) EPS and FY2027 earnings at ($0.90) EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analysts’ expectations of $3.70 million.

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Monday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. Canaccord Genuity Group dropped their target price on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 7th. JPMorgan Chase & Co. boosted their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Finally, TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $11.48 on Friday. Stoke Therapeutics has a one year low of $3.35 and a one year high of $16.40. The business’s 50 day simple moving average is $10.47 and its two-hundred day simple moving average is $6.81. The stock has a market capitalization of $598.34 million, a P/E ratio of -4.76 and a beta of 0.82.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 5,126 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the transaction, the general counsel now owns 2,598 shares in the company, valued at approximately $34,293.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, major shareholder Skorpios Trust sold 3,600,000 shares of Stoke Therapeutics stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 5,126 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the completion of the sale, the general counsel now owns 2,598 shares in the company, valued at approximately $34,293.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,622,741 shares of company stock worth $41,935,115. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. GSA Capital Partners LLP raised its stake in Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after buying an additional 291,443 shares during the last quarter. Trexquant Investment LP raised its position in shares of Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock worth $503,000 after purchasing an additional 79,785 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Stoke Therapeutics by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock worth $576,000 after purchasing an additional 12,478 shares during the last quarter. Corton Capital Inc. bought a new position in Stoke Therapeutics in the 3rd quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at about $64,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.